Showing posts with label First. Show all posts
Showing posts with label First. Show all posts

Sunday, April 10, 2011

New Approaches To Dementia And Sight Loss - Report Of First National Conference Released Today, UK

Translate Request has too much data
Parameter name: request

Main Category: Alzheimer's / Dementia
Also Included In: Eye Health / Blindness
Article Date: 16 Mar 2011 - 1:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
5 starsnot yet rated
Key messages for professionals, policy makers, commissioners and carers are highlighted in a report released today (1) of the First National Conference on Dementia and Sight Loss.

The report, by the Dementia and Sight Loss Interest Group (DaSLIG), a coalition of leading charities, (2) summarises the presentations and discussions delivered at the recent National Conference in London. Organised by DaSLIG and sponsored by ARUP, the conference brought together over 70 delegates - sight loss and dementia specialists as well as representatives from bodies including the Department of Health, NHS and Social Care Institute for Excellence.

"This conference was a milestone in the bid to improve the lives of people living with both dementia and sight loss," said Sarah Buchanan, Research and Development Manager, Thomas Pocklington Trust. "It was the first major debate on this issue and it delivered crucial information and practical solutions for improving care. The report should be essential reading for all those involved in the care and support of people with dementia."

Of the estimated 750,000 people in the UK living with dementia, at least 100,000 will also have serious sight loss yet, in 2010, a review of existing dementia policy, practice and literature, summarised for the conference by Dr. Declan McKeefry (3), (Bradford University School of Optometry and Vision Science), concluded that all three displayed a "fundamental lack of sensitivity to sight loss."

He highlighted three main types of sight loss associated with dementia. A specific eye condition might occur at the same time as dementia; some forms of dementia affect vision, including perception of colour, depth and detail; and, thirdly, normal ageing of the eyes plays an important role since most people with dementia are over the age of 75.

Despite this, his research showed that few people with dementia appear to have access to regular eye tests.

"Ocular health screening is important in people with dementia, yet there's a reticence to refer them," he said.

At the conference, Fazilet Hadi, Group Director Inclusive Society, RNIB, spelled out the realities of living with dementia and sight loss. The emotional impact on people's identity, confidence and self worth are underestimated and a lot of people are not getting the services they need.

"Having both dementia and sight loss is qualitatively different than having one or the other. But when dementia is the main condition sight loss can be forgotten," she said.

Dr. Graham Stokes, Director of Dementia Care for BUPA, had seen many cases of dementia related sight loss. He called it "not seeing with true knowledge". In a moving account he described a man whose dementia and sight loss led to terror at his own reflection. Too often carers were insensitive to this kind of fear and alarm. He classified this as "malign care" and urged carers to "move beyond quality of care to quality of life." He listed practical examples for improving care in care homes. For example: how to deliver "high intensity engagement" to people with dementia. Even 90 seconds of interaction can give long-lasting feelings of wellbeing:

"The positive feeling exists far longer than the memory of the interaction," he said. "Carers, you do have time to give people one-to-one attention."

The National Dementia Strategy was setting a pathway for change, said Professor Sube Banerjee, leading specialist in dementia and co-leader on development of the national strategy.

"At the moment we spend a lot of money - late - on things that aren't of good quality," he said.

He cited "waiting too long and not focussing on prevention" as major failings. Late diagnosis was resulting in "harm, crisis and cost," he said, with only 30% of people with dementia ever diagnosed. Now, early diagnosis and intervention "including the diagnosis of important co-morbidities such as sight loss" is a key aim of the National Dementia Strategy.

The huge cost of dementia care - £17 billion a year in the UK - would be a powerful driver of change:

"Doing dementia care well will cost less than doing it badly. Doing it well becomes the solution rather than the problem."

Andrew Chidgey, Head of Policy and Public Affairs at the Alzheimer's Society, said the scene was set for achieving change.

"There is a willingness of people to talk more freely about members of their family who have dementia. With this increased awareness and willingness to act there is an opportunity now to do far more on dementia linked to sight loss."

Other speakers highlighted in the report include:

Professor David Croisdale-Appleby OBE (Skills for Care) on how qualifications available from January 2011 will improve the knowledge, understanding and status of social care staff.

Penny Redwood (freelance trainer) on how to recognise concurrent sight loss and dementia.

Pam Turpin, (ARUP) giving a room-by-room account of making a home dementia and sight loss friendly.

Notes:

1. Dementia and Sight Loss Conference - Summary of Conference available here.

2. The Dementia and Sight Loss Interest Group (DaSLIG) of VISION 2020 UK is led by Alzheimer's Society, Macular Disease Society, ARUP, Royal National Institute of Blind People (RNIB) and Thomas Pocklington Trust. This special interest group leads work to raise awareness of concurrent dementia and sight loss.

3. Research papers available here.
The key papers presented by Professor Sube Banerjee and Dr. Declan McKeefry are:
"The experiences and needs of people with dementia and serious visual impairment: a qualitative study" by Vanessa Lawrence, Joanna Murray, Dr. Dominic ffytche and Professor Sube Banerjee, King's College London.
"The development of professional guidelines for the eye examination of people with dementia" D. McKeefry. University of Bradford Schools of Optometry and Vision Science. The findings of this study are included in Thomas Pocklington Trust Research Discussion Paper number 8 - "Improving the provision of vision and eye health care to people with dementia"

4. The research led by Professor Sube Banerjee at Kings College, London, and supported by Thomas Pocklington Trust, shows that in dementia a person's orientation, recognition, recall and judgement are all exacerbated by sight loss, making the impact of dementia worse. Sight loss can increase feelings of confusion, isolation and fear and this, in turn, may trigger aggression. At the same time, a person's ability to cope with sight loss is reduced by dementia. Responding to people's sight loss, suggests the research, could reduce both the distress of dementia and the likelihood of disruptive behaviour.

Source:
Thomas Pocklington Trust

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

posted by Jim on 26 Mar 2011 at 12:11 am

My wife Patricia was diagnosed with alzheimers in 2000 at the age of 57. Her eyes are perfect, but the brain cells for seeing have died. She had trouble seeing in 1998, and is now blind. It is advisable to be checked out for alz if one is having to use spectacles for the first time at 35 years and over. Alzheimers may be the cause.

| post followup | alert a moderator |


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Saturday, April 9, 2011

Researchers Develop The First Permanent Anti-Fog Coating


Main Category: Medical Devices / Diagnostics
Also Included In: Eye Health / Blindness
Article Date: 17 Mar 2011 - 3:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
5 stars5 stars
Researchers under the supervision of Université Laval professor Gaétan Laroche have developed the very first permanent anti-fog coating. Dr. Laroche and his colleagues present in the online edition of Applied Materials and Interfaces the details of this innovation which could eliminate, once and for all, the fog on eyeglasses, windshields, goggles, camera lenses, and on any transparent glass or plastic surface.

Fog forms on a surface when water vapor in the air condenses in fine droplets. "Despite appearances, the fog that forms on glasses is not a continuous film. In fact, it consists of tiny droplets of water that coalesce on the surface and reduce light transmission," explains Laroche, a professor at Université Laval's Faculty of Sciences and Engineering. "A good anti-fog coating should prevent the formation of such droplets."

Researchers used polyvinyl alcohol, a hydrophilic compound that allows water to spread uniformly. The challenge was to firmly attach the compound to the glass or plastic surface. To accomplish this, researchers applied four successive layers of molecules, which formed strong bonds with their adjoining layers, prior to adding the anti-fog compound over this base. The result was a thin, transparent, multilayered coating that does not alter the optical properties of the surface on which it is overlaid. In addition, the chemical bonds that join the different layers ensure the hardness and durability of the entire coating.

"Existing anti-fog treatments don't have these properties and won't withstand washing, so the product application must be repeated regularly," notes Professor Laroche. "Our coating, on the other hand, is permanent."

Two patents already protect this invention, which has numerous potential applications, including vehicle windshields, protective visors, camera lenses, binoculars, optical instruments used in chemistry and medicine, and corrective lenses. Negotiations are already underway with a major eyewear company interested in obtaining a license for this technology.

In addition to Gaétan Laroche, the study published in Applied Materials and Interfaces was coauthored by Pascale Chevallier, Stéphane Turgeon, Christian Sarra-Bournet, and Raphaël Turcotte.

Source:
Université Laval

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Wednesday, March 23, 2011

Brain Tumor Blasting Device Clears First Hurdle With FDA - Seattle Patient Advocate Applauds Vote As "Victory For Patients"


Main Category: Medical Devices / Diagnostics
Also Included In: Regulatory Affairs / Drug Approvals;  Cancer / Oncology;  Neurology / Neuroscience
Article Date: 21 Mar 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
5 starsnot yet rated
Calling it "a great day for brain cancer patients," national patient advocate, Dellann Elliott, president and CEO of the Seattle-based Chris Elliott Fund, applauded a Food and Drug Administration (FDA) panel's vote to back a new brain tumor-blasting device called NovoTTF. Elliott testified before the Neurological Devices Panel of the Medical Devices Advisory Committee to the FDA on Thurs., March 17th in Washington, D.C., calling on the panel to "give brain cancer patients more treatment options and more hope for an incurable disease." Final approval of the device is expected within the next 3 months.

"This is a great day for brain cancer patients," says Elliott, "Access to cutting-edge treatments like NovoCure's NovoTTF means more options and more hope for patients battling brain cancer. This is what patients and doctors need to maintain this disease."

Elliott added that FDA approval of NovoTTF means more patients will be able to participate in clinical trials including those in Seattle at the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute in Seattle. The Chris Elliott Fund works closely with the Ivy Center and funds their Integrated Patient Support Program.

Dr. Greg Foltz, neurosurgeon and director of the Ivy Center, says Elliott has changed the way brain cancer patients are treated in Washington state. "Through patient advocacy within the medical community and patient education, more people are getting access to advanced treatments. She understands that you have to fight this disease from every angle," Foltz says.

Elliott's work through the Chris Elliott Fund focuses on glioblastoma (GBM) - the deadliest form of brain cancer. More than 22,000 Americans are diagnosed with a malignant brain cancer every year. It is the leading cause of cancer-related deaths for children under 19. About 60 to 70 percent of these cancers are GBM with a life expectancy after diagnosis of 12 to 14 months.

Glioblastoma is the same type of brain cancer that took the life of Massachusetts Senator Ted Kennedy, and Elliott's husband, Chris Elliott.

"This type of brain cancer is the death sentence of our time like what HIV was 30 years ago, but it doesn't have to be that way," says Elliott, "the fact that it is incurable today, does not mean that it is not treatable. While HIV is not curable, it is manageable and patients are living longer and healthier lives with aggressive treatment."

Elliott added that with so few advanced treatments available most patients go through 1 to 2 years of standard treatment and are not treated at a brain tumor center recognized for its excellence. "Too often the most common prognosis for a GBM patient and their family is ?there is nothing more we can do," says Elliott. "I hear from patients all over the world that all they want is to have their survival optimized. Access to cutting-edge treatments like NovoCure's device, NovoTTF, creates hope and adds treatment options - it's about buying more time to find a cure."

Harvard University honored Elliott in 2008 with the National Patient Advocate award in recognition of her extensive work in promoting advanced treatment for GBM patients and public awareness about the disease.

"What we have found is that every brain tumor is unique in many ways and that standard treatment can't address these issues for the patient," says Elliott. "Our goal is to make sure that every brain cancer patient knows that they can access advanced treatments and get genetic testing of their tumor to better optimize their chances of beating this disease."

Elliott lost her husband, Chris, in 2002 after a 2-year battle with GBM. He was 41. "It was unacceptable to us that there were so few treatments available. We vowed to make sure other people and their loved ones facing this disease would have more options and more hope," Elliott says. Three weeks before Chris died, they founded the Chris Elliott Fund (CEF) for Glioblastoma Brain Cancer Research in May 2002.

Since 2002, CEF has raised over $1 million for brain cancer research and is recognized as a national model for patient advocacy. CEF funds groundbreaking research at the Christopher S.

Elliott Neuro-oncology Lab for Glioblastoma Brain Research and Applied Science Center at the Dana-Faber Cancer Institute in Boston, Mass., and the Integrated Patient Support Program at the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment in Seattle's Swedish Neuroscience Institute.

Source:
Chris Elliott Fund

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here